TY - JOUR AU - Pasquali, S. AU - Hadjinicolaou, A. V. AU - Chiarion Sileni, V. AU - Rossi, C. R. AU - Mocellin, S. PY - 2018 DA - 2018// TI - Systemic treatments for metastatic cutaneous melanoma JO - Cochrane Database Syst Rev VL - 2 UR - https://doi.org/10.1002/14651858.CD011123.pub2 DO - 10.1002/14651858.CD011123.pub2 ID - Pasquali2018 ER - TY - JOUR AU - Garbe, C. AU - Eigentler, T. K. AU - Keilholz, U. AU - Hauschild, A. AU - Kirkwood, J. M. PY - 2011 DA - 2011// TI - Systematic review of medical treatment in melanoma: current status and future prospects JO - Oncologist. VL - 16 UR - https://doi.org/10.1634/theoncologist.2010-0190 DO - 10.1634/theoncologist.2010-0190 ID - Garbe2011 ER - TY - JOUR AU - Molife, R. AU - Hancock, B. W. PY - 2002 DA - 2002// TI - Adjuvant therapy of malignant melanoma JO - Crit Rev Oncol Hematol VL - 44 UR - https://doi.org/10.1016/S1040-8428(02)00014-8 DO - 10.1016/S1040-8428(02)00014-8 ID - Molife2002 ER - TY - BOOK PY - 2019 DA - 2019// TI - NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Cutaneous Melanoma. Version 2.2020 ID - ref4 ER - TY - JOUR AU - Coit, D. G. AU - Thompson, J. A. AU - Albertini, M. R. AU - Barker, C. AU - Carson, W. E. AU - Contreras, C. PY - 2019 DA - 2019// TI - Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology JO - J Natl Compr Cancer Netw VL - 17 UR - https://doi.org/10.6004/jnccn.2019.0018 DO - 10.6004/jnccn.2019.0018 ID - Coit2019 ER - TY - JOUR AU - Dummer, R. AU - Hauschild, A. AU - Lindenblatt, N. AU - Pentheroudakis, G. AU - Keilholz, U. PY - 2015 DA - 2015// TI - Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv297 DO - 10.1093/annonc/mdv297 ID - Dummer2015 ER - TY - JOUR AU - Hauschild, A. AU - Dummer, R. AU - Schadendorf, D. AU - Santinami, M. AU - Atkinson, V. AU - Mandalà, M. PY - 2018 DA - 2018// TI - Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.18.01219 DO - 10.1200/JCO.18.01219 ID - Hauschild2018 ER - TY - JOUR AU - Eggermont, A. M. M. AU - Blank, C. U. AU - Mandala, M. AU - Long, G. V. AU - Atkinson, V. G. AU - Dalle, S. PY - 2019 DA - 2019// TI - Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma JO - Eur J Cancer VL - 116 UR - https://doi.org/10.1016/j.ejca.2019.05.020 DO - 10.1016/j.ejca.2019.05.020 ID - Eggermont2019 ER - TY - JOUR AU - Eggermont, A. M. M. AU - Chiarion-Sileni, V. AU - Grob, J. J. AU - Dummer, R. AU - Wolchok, J. D. AU - Schmidt, H. PY - 2019 DA - 2019// TI - Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial JO - Eur J Cancer VL - 119 UR - https://doi.org/10.1016/j.ejca.2019.07.001 DO - 10.1016/j.ejca.2019.07.001 ID - Eggermont2019 ER - TY - JOUR AU - Kirkwood, J. M. AU - Strawderman, M. H. AU - Ernstoff, M. S. AU - Smith, T. J. AU - Borden, E. C. AU - Blum, R. H. PY - 1996 DA - 1996// TI - Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684 JO - J Clin Oncol VL - 14 UR - https://doi.org/10.1200/JCO.1996.14.1.7 DO - 10.1200/JCO.1996.14.1.7 ID - Kirkwood1996 ER - TY - BOOK PY - 2018 DA - 2018// TI - Yervoy (ipilimumab) ID - ref11 ER - TY - BOOK PY - 2018 DA - 2018// TI - Opdivo (nivolumab) ID - ref12 ER - TY - BOOK PY - 2018 DA - 2018// TI - Keytruda (pembrolizumab) ID - ref13 ER - TY - STD TI - FDA approves dabrafenib plus trametinib for adjuvant treatment of melanoma with BRAF V600E or V600K mutations. US Food and Drug Administration website. 2018. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-plus-trametinib-adjuvant-treatment-melanoma-braf-v600e-or-v600k-mutations. Accessed 30 Sept 2019. UR - https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-plus-trametinib-adjuvant-treatment-melanoma-braf-v600e-or-v600k-mutations ID - ref14 ER - TY - JOUR AU - Weber, J. AU - Mandala, M. AU - Vecchio, M. AU - Gogas, H. J. AU - Arance, A. M. AU - Cowey, C. L. PY - 2017 DA - 2017// TI - Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1709030 DO - 10.1056/NEJMoa1709030 ID - Weber2017 ER - TY - JOUR AU - Dias, S. AU - Welton, N. J. AU - Sutton, A. J. AU - Caldwell, D. M. AU - Lu, G. AU - Ades, A. E. PY - 2013 DA - 2013// TI - Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials JO - Med Decis Mak VL - 33 UR - https://doi.org/10.1177/0272989X12455847 DO - 10.1177/0272989X12455847 ID - Dias2013 ER - TY - JOUR AU - Jansen, J. P. AU - Naci, H. PY - 2013 DA - 2013// TI - Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers JO - BMC Med VL - 11 UR - https://doi.org/10.1186/1741-7015-11-159 DO - 10.1186/1741-7015-11-159 ID - Jansen2013 ER - TY - JOUR AU - Sharma, R. AU - Koruth, R. AU - Kanters, S. AU - Druyts, E. AU - Tarhini, A. PY - 2019 DA - 2019// TI - Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma JO - J Comp Eff Res VL - 8 UR - https://doi.org/10.2217/cer-2019-0061 DO - 10.2217/cer-2019-0061 ID - Sharma2019 ER - TY - JOUR AU - Lorenzi, M. AU - Arndorfer, S. AU - Aguiar-Ibañez, R. AU - Scherrer, E. AU - Liu, F. X. AU - Krepler, C. PY - 2019 DA - 2019// TI - An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma JO - J Drug Assess VL - 8 UR - https://doi.org/10.1080/21556660.2019.1649266 DO - 10.1080/21556660.2019.1649266 ID - Lorenzi2019 ER - TY - JOUR AU - Jansen, J. P. PY - 2011 DA - 2011// TI - Network meta-analysis of survival data with fractional polynomials JO - BMC Med Res Methodol VL - 11 UR - https://doi.org/10.1186/1471-2288-11-61 DO - 10.1186/1471-2288-11-61 ID - Jansen2011 ER - TY - JOUR AU - Ouwens, M. J. N. M. AU - Philips, Z. AU - Jansen, J. P. PY - 2011 DA - 2011// TI - Network meta-analysis of parametric survival curves JO - Res Synth Methods VL - 1 UR - https://doi.org/10.1002/jrsm.25 DO - 10.1002/jrsm.25 ID - Ouwens2011 ER - TY - JOUR AU - Agarwala, S. S. AU - Lee, S. J. AU - Yip, W. AU - Rao, U. N. AU - Tarhini, A. A. AU - Cohen, G. I. PY - 2017 DA - 2017// TI - Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the eastern cooperative oncology group–American College of Radiology Imaging Network cancer research group (E1697) JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.70.2951 DO - 10.1200/JCO.2016.70.2951 ID - Agarwala2017 ER - TY - JOUR AU - Cameron, D. A. AU - Cornbleet, M. C. AU - Mackie, R. M. AU - Hunter, J. A. AU - Gore, M. AU - Hancock, B. PY - 2001 DA - 2001// TI - Adjuvant interferon alpha 2b in high risk melanoma — the Scottish study JO - Br J Cancer VL - 84 UR - https://doi.org/10.1054/bjoc.2000.1623 DO - 10.1054/bjoc.2000.1623 ID - Cameron2001 ER - TY - JOUR AU - Cascinelli, N. AU - Belli, F. AU - MacKie, R. M. AU - Santinami, M. AU - Bufalino, R. AU - Morabito, A. PY - 2001 DA - 2001// TI - Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial JO - Lancet. VL - 358 UR - https://doi.org/10.1016/S0140-6736(01)06068-8 DO - 10.1016/S0140-6736(01)06068-8 ID - Cascinelli2001 ER - TY - JOUR AU - Eggermont, A. M. AU - Chiarion-Sileni, V. AU - Grob, J. J. AU - Dummer, R. AU - Wolchok, J. D. AU - Schmidt, H. PY - 2015 DA - 2015// TI - Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70122-1 DO - 10.1016/S1470-2045(15)70122-1 ID - Eggermont2015 ER - TY - JOUR AU - Eggermont, A. M. AU - Suciu, S. AU - MacKie, R. AU - Ruka, W. AU - Testori, A. AU - Kruit, W. PY - 2005 DA - 2005// TI - Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial JO - Lancet VL - 366 UR - https://doi.org/10.1016/S0140-6736(05)67482-X DO - 10.1016/S0140-6736(05)67482-X ID - Eggermont2005 ER - TY - JOUR AU - Eggermont, A. M. AU - Suciu, S. AU - Santinami, M. AU - Testori, A. AU - Kruit, W. H. AU - Marsden, J. PY - 2008 DA - 2008// TI - Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial JO - Lancet VL - 372 UR - https://doi.org/10.1016/S0140-6736(08)61033-8 DO - 10.1016/S0140-6736(08)61033-8 ID - Eggermont2008 ER - TY - BOOK PY - 2019 DA - 2019// TI - Keytruda: European Public Assessment Report (EPAR) - Product Information ID - ref28 ER - TY - JOUR AU - Eggermont, A. M. M. AU - Blank, C. U. AU - Mandala, M. AU - Long, G. V. AU - Atkinson, V. AU - Dalle, S. PY - 2018 DA - 2018// TI - Adjuvant pembrolizumab versus placebo in resected stage III melanoma JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1802357 DO - 10.1056/NEJMoa1802357 ID - Eggermont2018 ER - TY - JOUR AU - Flaherty, L. E. AU - Othus, M. AU - Atkins, M. B. AU - Tuthill, R. J. AU - Thompson, J. A. AU - Vetto, J. T. PY - 2014 DA - 2014// TI - Southwest oncology group S0008: a phase III trial of high-dose interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma—an intergroup study of cancer and leukemia group B, Children's oncology group, eastern cooperative oncology group, and southwest oncology group JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.53.1590 DO - 10.1200/JCO.2013.53.1590 ID - Flaherty2014 ER - TY - JOUR AU - Garbe, C. AU - Radny, P. AU - Linse, R. AU - Dummer, R. AU - Gutzmer, R. AU - Ulrich, J. PY - 2008 DA - 2008// TI - Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis JO - Ann Oncol VL - 19 UR - https://doi.org/10.1093/annonc/mdn001 DO - 10.1093/annonc/mdn001 ID - Garbe2008 ER - TY - JOUR AU - Hancock, B. W. AU - Wheatley, K. AU - Harris, S. AU - Ives, N. AU - Harrison, G. AU - Horsman, J. M. PY - 2004 DA - 2004// TI - Adjuvant interferon in high-risk melanoma: the AIM HIGH study—United Kingdom coordinating committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.03.185 DO - 10.1200/JCO.2004.03.185 ID - Hancock2004 ER - TY - JOUR AU - Hansson, J. AU - Aamdal, S. AU - Bastholt, L. AU - Brandberg, Y. AU - Hernberg, M. AU - Nilsson, B. PY - 2011 DA - 2011// TI - Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(10)70288-6 DO - 10.1016/S1470-2045(10)70288-6 ID - Hansson2011 ER - TY - JOUR AU - Kim, K. B. AU - Legha, S. S. AU - Gonzalez, R. AU - Anderson, C. M. AU - Johnson, M. M. AU - Liu, P. PY - 2009 DA - 2009// TI - A randomized phase III trial of biochemotherapy versus interferon-alpha- 2b for adjuvant therapy in patients at high risk for melanoma recurrence JO - Melanoma Res VL - 19 UR - https://doi.org/10.1097/CMR.0b013e328314b84a DO - 10.1097/CMR.0b013e328314b84a ID - Kim2009 ER - TY - JOUR AU - Kirkwood, J. M. AU - Ibrahim, J. G. AU - Sondak, V. K. AU - Richards, J. AU - Flaherty, L. E. AU - Ernstoff, M. S. PY - 2000 DA - 2000// TI - High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 JO - J Clin Oncol VL - 18 UR - https://doi.org/10.1200/JCO.2000.18.12.2444 DO - 10.1200/JCO.2000.18.12.2444 ID - Kirkwood2000 ER - TY - JOUR AU - Kleeberg, U. R. AU - Suciu, S. AU - Bröcker, E. B. AU - Ruiter, D. J. AU - Chartier, C. AU - Lienard, D. PY - 2004 DA - 2004// TI - Final results of the EORTC 18871/DKG 80–1 randomised phase III trial: rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis JO - Eur J Cancer VL - 40 UR - https://doi.org/10.1016/j.ejca.2003.07.004 DO - 10.1016/j.ejca.2003.07.004 ID - Kleeberg2004 ER - TY - JOUR AU - Long, G. V. AU - Hauschild, A. AU - Santinami, M. AU - Atkinson, V. AU - Mandalà, M. AU - Chiarion-Sileni, V. PY - 2017 DA - 2017// TI - Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1708539 DO - 10.1056/NEJMoa1708539 ID - Long2017 ER - TY - JOUR AU - Stadler, R. AU - Luger, T. AU - Bieber, T. AU - Köhler, U. AU - Linse, R. AU - Technau, K. PY - 2006 DA - 2006// TI - Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: a controlled, randomised multicentre trial JO - Acta Oncol VL - 45 UR - https://doi.org/10.1080/02841860600630954 DO - 10.1080/02841860600630954 ID - Stadler2006 ER - TY - STD TI - Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, et al. A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms. J Clin Oncol. 2017;35(Suppl) Abstract 9500. https://doi.org/10.1200/JCO.2017.35.15_suppl.9500. ID - ref39 ER - TY - STD TI - Weber J, Del Vecchio M, Mandala M, Gogas HJ, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 trial. Presented at ESMO 2019; 27 Sept–1 Oct 2019; Barcelona, Spain. ID - ref40 ER - TY - JOUR AU - Eigentler, T. K. AU - Gutzmer, R. AU - Hauschild, A. AU - Heinzerling, L. AU - Schadendorf, D. AU - Nashan, D. PY - 2016 DA - 2016// TI - Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw225 DO - 10.1093/annonc/mdw225 ID - Eigentler2016 ER - TY - JOUR AU - Grob, J. J. AU - Jouary, T. AU - Dréno, B. AU - Asselineau, J. AU - Gutzmer, R. AU - Hauschild, A. PY - 2013 DA - 2013// TI - Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.07.018 DO - 10.1016/j.ejca.2012.07.018 ID - Grob2013 ER - TY - JOUR AU - Lian, B. AU - Si, L. AU - Cui, C. AU - Chi, Z. AU - Sheng, X. AU - Mao, L. PY - 2013 DA - 2013// TI - Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0739 DO - 10.1158/1078-0432.CCR-13-0739 ID - Lian2013 ER - TY - JOUR AU - McMasters, K. M. AU - Egger, M. E. AU - Edwards, M. J. AU - Ross, M. I. AU - Reintgen, D. S. AU - Noyes, R. D. PY - 2016 DA - 2016// TI - Final results of the sunbelt melanoma trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.63.3776 DO - 10.1200/JCO.2015.63.3776 ID - McMasters2016 ER - TY - JOUR AU - Mohr, P. AU - Hauschild, A. AU - Trefzer, U. AU - Enk, A. AU - Tilgen, W. AU - Loquai, C. PY - 2015 DA - 2015// TI - Intermittent high-dose intravenous interferon alfa-2b for adjuvant treatment of stage III melanoma: final analysis of a randomized phase III dermatologic cooperative oncology group trial JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.6932 DO - 10.1200/JCO.2014.59.6932 ID - Mohr2015 ER - TY - JOUR AU - Tobin, R. P. AU - Jordan, K. R. AU - Robinson, W. A. AU - Davis, D. AU - Borges, V. F. AU - Gonzalez, R. PY - 2018 DA - 2018// TI - Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab JO - Int Immunopharmacol VL - 63 UR - https://doi.org/10.1016/j.intimp.2018.08.007 DO - 10.1016/j.intimp.2018.08.007 ID - Tobin2018 ER - TY - STD TI - Wang X, Mao LL, Si L, Chi Z, Cui C, Nan X, et al. Efficacy of high-dose adjuvant interferon therapy in high-risk melanoma harboring gene mutations. J Clin Oncol. 2015;33(Suppl) Abstract 9047. https://doi.org/10.1200/jco.2015.33.15_suppl.9047. ID - ref47 ER -